Azithromycin-Containing Regimens for Treatment of Mycobacterium avium Complex Lung Disease

This publication has 20 references indexed in Scilit:

• Early Results (at 6 Months) with Intermittent Clarithromycin-Including Regimens for Lung Disease Due to Mycobacterium avium Complex
  Clinical Infectious Diseases, 2000
• A Randomized, Placebo‐Controlled Study of Rifabutin Added to a Regimen of Clarithromycin and Ethambutol for Treatment of Disseminated Infection with Mycobacterium avium Complex
  Clinical Infectious Diseases, 1999
• Randomized, Open‐Label Trial of Azithromycin Plus Ethambutol vs. Clarithromycin Plus Ethambutol as Therapy forMycobacterium aviumComplex Bacteremia in Patients with Human Immunodeficiency Virus Infection
  Clinical Infectious Diseases, 1998
• Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria
  American Journal of Respiratory and Critical Care Medicine, 1997
• Azithromycin Activity Against Mycobacterium avium Complex Lung Disease in Patients Who Were Not Infected with Human Immunodeficiency Virus
  Clinical Infectious Diseases, 1996
• Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients.
  American Journal of Respiratory and Critical Care Medicine, 1996
• Mycobacterium avium disease: progress at last.
  American Journal of Respiratory and Critical Care Medicine, 1996
• Reduced Serum Levels Of Clarithromycin In Patients Treated With Multi-Drug Regimens Including Rifampin Or Rifabutin For Mycobacterium Avium-M. Intracellulare Infection
  The Journal of Infectious Diseases, 1995
• Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease.
  American Journal of Respiratory and Critical Care Medicine, 1994
• Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system
  Antimicrobial Agents and Chemotherapy, 1992